These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23665884)

  • 1. Vildagliptin with metformin once-daily regimen-insights from a single-center analysis.
    Chatterjee S; Chatterjee S
    Am J Ther; 2015; 22(3):195-8. PubMed ID: 23665884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).
    Hermans M; Van Gaal L; Rézette I; Daci E; MacDonald K; Denhaerynck K; Vancayzeele S; De Meester L; Clemens A; Yee B; Abraham I
    Prim Care Diabetes; 2016 Dec; 10(6):425-433. PubMed ID: 27388795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.
    Marfella R; Barbieri M; Grella R; Rizzo MR; Nicoletti GF; Paolisso G
    J Diabetes Complications; 2010; 24(2):79-83. PubMed ID: 19261490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
    Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
    Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
    Ahrén B; Foley JE; Bosi E
    Diabetes Obes Metab; 2011 Mar; 13(3):193-203. PubMed ID: 21205107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
    Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
    Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
    Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
    Vianna AGD; Lacerda CS; Pechmann LM; Polesel MG; Marino EC; Faria-Neto JR
    Diabetes Res Clin Pract; 2018 May; 139():357-365. PubMed ID: 29596951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study.
    Chatterjee S; Chatterjee S
    J Diabetes; 2014 May; 6(3):237-42. PubMed ID: 23879210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes.
    He YL; Sabo R; Picard F; Wang Y; Herron J; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2009 May; 25(5):1265-72. PubMed ID: 19364302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Filozof C; Gautier JF
    Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
    Bosi E; Dotta F; Jia Y; Goodman M
    Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose.
    Nomoto H; Kimachi K; Miyoshi H; Kameda H; Cho KY; Nakamura A; Nagai S; Kondo T; Atsumi T
    Endocr J; 2017 Apr; 64(4):417-424. PubMed ID: 28260702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.
    Halimi S; Schweizer A; Minic B; Foley J; Dejager S
    Vasc Health Risk Manag; 2008; 4(3):481-92. PubMed ID: 18827867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes.
    Tasci I; Naharci MI; Bozoglu E; Safer U; Aydogdu A; Yilmaz BF; Yilmaz G; Doruk H
    Endocr Metab Immune Disord Drug Targets; 2013 Sep; 13(3):256-63. PubMed ID: 23848558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
    He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
    Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
    Kitao N; Miyoshi H; Furumoto T; Ono K; Nomoto H; Miya A; Yamamoto C; Inoue A; Tsuchida K; Manda N; Kurihara Y; Aoki S; Nakamura A; Atsumi T;
    Cardiovasc Diabetol; 2017 Oct; 16(1):125. PubMed ID: 29017497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.